The AHA Sept. 9 released a report highlighting how hospitals’ arrangements with community and specialty pharmacies improve access to care for underserved patients.

“The accessibility of community pharmacies presents a convenient, familiar, and dependable source of care,” the report notes. “This is especially true for those living in rural communities or who lack easy access to transportation.”

The report includes a number of data points on how 340B community and specialty pharmacies are located in counties that are experiencing issues that affect individuals’ health, including lack of insurance, food insecurity, high unemployment and severe housing problems.

“Importantly, these arrangements allow hospitals to better fulfill their 340B mission — to stretch scarce resources and expand access to care for more patients,” the report notes. “Collectively these data demonstrate the need for Congress to continue its strong bipartisan support of the program and reject efforts by big drug companies to undermine the program and the innumerable benefits it affords patients across the country.”
 

Related News Articles

Headline
The 1st U.S. Circuit Court of Appeals Jan. 7 denied the government’s motion for a stay in a lawsuit filed by the AHA, the Maine Hospital Association and four…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Blog
Public
Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4…
Headline
The AHA, the Maine Hospital Association and four safety-net health systems from across the country Dec. 1 filed a lawsuit in the U.S. District…
Chairperson's File
Public
For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription…
Chairperson's File
Public
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…